A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
NCT01497470
Completed
The primary goal of this study is to determine if custirsen has an effect on the way the body distributes and gets rid of paclitaxel, the standard administered chemotherapy. The study will also evaluate if custirsen influences the way the body distributes and gets rid of carboplatin (another standard administered chemotherapy) and will measure custirsen blood levels in this cancer population. Finally, the study will evaluate the safety and tolerability of adding custirsen to the standard paclita... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2016
Locations: Teva Investigational Site 001, Dallas, Texas +1 locations
Conditions: Cancer
Register for Updates
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
NCT00874848
Completed
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/06/2016
Locations: Mary Crowley Medical Research Center, Dallas, Texas +1 locations
Conditions: NSCLC
Register for Updates
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
NCT01454089
Completed
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2016
Locations: Texas Oncology, P.A., Dallas, Texas
Conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
Register for Updates
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
NCT00303108
Completed
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2016
Locations: Texas Cancer Center - Abilene (South), Abilene, Texas +26 locations
Conditions: Metastatic Breast Cancer
Register for Updates
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
NCT00682981
Completed
The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: Baylor, Dallas, Texas +2 locations
Conditions: Extensive-stage Small Cell Lung Cancer
Register for Updates
Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT00033553
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor to plan treatment may result in more effective radiation therapy. It is not yet known which chemotherapy and/or radiation therapy regimen is more effective in treating non-small cell lung cancer. PURPOSE: Randomized phase II trial... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2016
Locations: Veterans Affairs Medical Center - Dallas, Dallas, Texas
Conditions: Lung Cancer
Register for Updates
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
NCT00382811
Completed
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may result.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/13/2016
Locations: Hope Cancer Clinic, Brownsville, Texas +2 locations
Conditions: Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
Register for Updates
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00070486
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib and zileuton may stop the growth of tumor cells by stopping blood flow to the tumor and may block the enzymes necessary for tumor cell growth. Combining chemotherapy with celecoxib and/or zileuton may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combining celecoxib and/or zileuton wi... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/28/2016
Locations: Veterans Affairs Medical Center - Dallas, Dallas, Texas +1 locations
Conditions: Lung Cancer
Register for Updates
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959
Completed
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford, Texas +8 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00112294
Completed
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2015
Locations: Local Institution, Amarillo, Texas +3 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
NCT00927589
Completed
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with HER2-positive metastatic or locally advanced inoperable cancer. The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. The QTcF interval is the QT interval as calculated using Fridericia's correction; the Q... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2015
Locations: Not set, Dallas, Texas +5 locations
Conditions: Solid Cancers
Register for Updates
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
NCT00894504
Completed
In this Phase II trial, the investigators will evaluate the combination of gemcitabine, carboplatin, and panitumumab in the treatment of patients with metastatic triple-negative breast cancer. In addition, to assess the efficacy of this combination, tumor tissue will be examined for the presence of various markers, including K-ras and PI3K-activating mutations, EGFR, PTEN, and p53. Correlation of tumor response with marker expression may define a patient subset that is particularly responsive to... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2015
Locations: Texas Health Physician Group, Dallas, Texas
Conditions: Metastatic Breast Cancer
Register for Updates